A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT03851081

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:19.961343+00:00

Published At

2022-01-28T00:00:00+00:00

Record Updated At

2022-01-28

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Allogeneic Hematopoietic Stem Cell Transplantation Recipient", "Blasts 5 Percent or More of Bone Marrow Nucleated Cells", "Blasts 5 Percent or More of Peripheral Blood White Cells", "CD22 Positive", "Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells", "Lymphoblasts 20 Percent or More of Peripheral Blood White Cells", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-01-28"

protocolSection.identificationModule.nctId

"NCT03851081"

protocolSection.identificationModule.officialTitle

"A Multi-Center, Open-Label Phase 1b/2 Study of Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Adult Patients With Relapsed/Refractory B Lineage Acute Lymphoblastic Leukemia (B-ALL)"

protocolSection.statusModule.overallStatus

"WITHDRAWN"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Allogeneic Hematopoietic Stem Cell Transplantation Recipient (protocolSection.conditionsModule.conditions)
• Blasts 5 Percent or More of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
• Blasts 5 Percent or More of Peripheral Blood White Cells (protocolSection.conditionsModule.conditions)
• CD22 Positive (protocolSection.conditionsModule.conditions)
• Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
• Lymphoblasts 20 Percent or More of Peripheral Blood White Cells (protocolSection.conditionsModule.conditions)
• Recurrent B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory B Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.